MENU

VTGN Stock VistaGen Therapeutics (VTGN, $2.39) Moving Average Convergence Divergence (MACD) Histogram turned negative on June 4, 2025

A.I.dvisor
at Tickeron.com
Loading...
VTGN - VistaGen Therapeutics
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $2.39
Daily change: $0 (0%)
Daily volume: 46.9K
Capitalization: $69M
Industry: Biotechnology
This is a Bearish indicator signaling VTGN's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 46 similar cases where VTGN's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

VTGN sees MACD Histogram crosses below signal line

VTGN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 04, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on VTGN as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VTGN broke above its upper Bollinger Band on May 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

VTGN moved above its 50-day moving average on May 16, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VTGN crossed bullishly above the 50-day moving average on May 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VTGN advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 134 cases where VTGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.840) is normal, around the industry mean (16.730). P/E Ratio (0.000) is within average values for comparable stocks, (60.095). VTGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.288). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (103.093) is also within normal values, averaging (259.914).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VTGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
VTGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of embryonic stem cells for drug discovery and development

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
343 Allerton Avenue
Phone
+1 650 577-3600
Employees
33
Web
https://www.vistagen.com